Literature DB >> 21572384

Recent progress in understanding pediatric pulmonary hypertension.

Steven H Abman1, D Dunbar Ivy.   

Abstract

PURPOSE OF REVIEW: Pulmonary artery hypertension (PAH) in children contributes significantly to morbidity and mortality in diverse pediatric cardiac, lung, hematologic and other diseases. Advances in pulmonary vascular biology over the past few decades have significantly expanded therapeutic strategies; however, many unique issues persist regarding our understanding of pediatric PAH. RECENT
FINDINGS: Recent studies of pediatric PAH include those that highlight gaps in our understanding of pediatric diseases associated with PAH from those of adult onset, emphasizing the strong need for specific studies regarding unique aspects of the pathogenesis and treatment of children with PAH. Registries have begun to provide new data showing differences in physiology, course, and genetics between adult and pediatric forms of PAH. Unfortunately, therapeutic strategies in pediatric pulmonary hypertension are often limited to small observational studies in children and are dependent on results from larger adult studies. In addition, clinical endpoints for studies and care remain poorly defined in infants and children.
SUMMARY: Despite many advances, long-term outcomes for children with PAH remain guarded and substantial challenges persist, especially with regard to understanding mechanisms and approach to severe PAH. Future studies are needed to develop novel biomarkers, clinical endpoints and interventions for young children with diverse causes of PAH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21572384      PMCID: PMC3128451          DOI: 10.1097/MOP.0b013e3283464a52

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  57 in total

1.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 3.  Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease.

Authors:  Steven H Abman
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  Inhibition of angiogenesis decreases alveolarization in the developing rat lung.

Authors:  M Jakkula; T D Le Cras; S Gebb; K P Hirth; R M Tuder; N F Voelkel; S H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-09       Impact factor: 5.464

5.  Medical therapy for pediatric pulmonary arterial hypertension.

Authors:  Cecile Tissot; David Dunbar Ivy; Maurice Beghetti
Journal:  J Pediatr       Date:  2010-07-24       Impact factor: 4.406

6.  Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension.

Authors:  Robin H Steinhorn; John P Kinsella; Christine Pierce; Ghazwan Butrous; Maria Dilleen; Michael Oakes; David L Wessel
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

7.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.

Authors:  Benjamin Sztrymf; Florence Coulet; Barbara Girerd; Azzedine Yaici; Xavier Jais; Olivier Sitbon; David Montani; Rogério Souza; Gerald Simonneau; Florent Soubrier; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

8.  Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

Authors:  D Dunbar Ivy; Aimee K Doran; Kelly J Smith; George B Mallory; Maurice Beghetti; Robyn J Barst; Daniela Brady; Yuk Law; Donna Parker; Lori Claussen; Steven H Abman
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

9.  Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; Adel Younoszai; D Dunbar Ivy; Steven H Abman
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124

10.  Primary pulmonary hypertension in children may have a different genetic background than in adults.

Authors:  Ekkehard Grünig; Rolf Koehler; Gabriel Miltenberger-Miltenyi; Rainer Zimmermann; Matthias Gorenflo; Derliz Mereles; Karlin Arnold; Barbara Naust; Heinrike Wilkens; Andreas Benz; Albrecht von Hippel; Herbert E Ulmer; Wolfgang Kübler; Hugo A Katus; Claus R Bartram; Dietmar Schranz; Bart Janssen
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

View more
  18 in total

Review 1.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

Review 2.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

3.  Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009.

Authors:  David B Frank; Matthew A Crystal; David L S Morales; Ken Gerald; Brian D Hanna; George B Mallory; Joseph W Rossano
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

4.  Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology.

Authors:  Karel Allegaert
Journal:  World J Clin Pediatr       Date:  2012-08-08

5.  Serum Pentraxin 3 and hs-CRP Levels in Children with Severe Pulmonary Hypertension.

Authors:  Cemşit Karakurt; Osman Başpınar; Fazlı Serkan Çelik; Çağatay Taşkapan; Aydın Derya Şahin; Saim Yoloğlu
Journal:  Balkan Med J       Date:  2014-09-01       Impact factor: 2.021

6.  Prevalence of Pulmonary Hypertension in Pediatric Patients With Obstructive Sleep Apnea and a Cardiology Evaluation: A Retrospective Analysis.

Authors:  Antoinette T Burns; Shana L Hansen; Zachary S Turner; James K Aden; Alexander B Black; Daniel P Hsu
Journal:  J Clin Sleep Med       Date:  2019-08-15       Impact factor: 4.062

Review 7.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

8.  A Retrospective Review of Infants Receiving Sildenafil.

Authors:  Aliva De; Payal Shah; Jacqueline Szmuszkovicz; Shazia Bhombal; Stanley Azen; Roberta M Kato
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 9.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

10.  Diagnosis and treatment of pulmonary hypertension in infancy.

Authors:  Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2013-09-29       Impact factor: 2.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.